Literature DB >> 19028998

Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme.

Deric M Park1, Gabrielle A Yeaney, Ronald L Hamilton, Jennifer Mabold, Nikki Urban, Leonard Appleman, John Flickinger, Frank Lieberman, Arlan Mintz.   

Abstract

Patients with Muir-Torre syndrome, an autosomal-dominant familial tumor condition caused by germline mutation of the DNA mismatch repair genes, MSH2 or MLH1, present with tumors of the sebaceous gland and visceral malignancies characterized by microsatellite instability. Here we show development of glioblastoma multiforme in a patient with Muir-Torre syndrome. Immunohistochemical analysis of the brain tumor and colon cancer revealed loss of the DNA mismatch repair gene detected by the genetic test, suggesting a pathogenic link.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028998      PMCID: PMC2743226          DOI: 10.1215/15228517-2008-101

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  10 in total

Review 1.  Muir-Torre syndrome.

Authors:  Giovanni Ponti; Maurizio Ponz de Leon
Journal:  Lancet Oncol       Date:  2005-12       Impact factor: 41.316

2.  The genetic basis of Muir-Torre syndrome includes the hMLH1 locus.

Authors:  B Bapat; L Xia; L Madlensky; A Mitri; P Tonin; S A Narod; S Gallinger
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

3.  Genetic factors in families with combined gastrointestinal and breast cancer.

Authors:  H T Lynch; A J Krush; H Guirgis
Journal:  Am J Gastroenterol       Date:  1973-01       Impact factor: 10.864

4.  Multiple sebaceous tumors.

Authors:  D Torre
Journal:  Arch Dermatol       Date:  1968-11

Review 5.  Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature.

Authors:  S Akhtar; K K Oza; S A Khan; J Wright
Journal:  J Am Acad Dermatol       Date:  1999-11       Impact factor: 11.527

6.  Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face.

Authors:  E G Muir; A J Bell; K A Barlow
Journal:  Br J Surg       Date:  1967-03       Impact factor: 6.939

7.  Muir-Torre syndrome in patients with hematologic malignancies.

Authors:  P R Cohen
Journal:  Am J Hematol       Date:  1992-05       Impact factor: 10.047

8.  Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene?

Authors:  R Kruse; C Lamberti; Y Wang; C Ruelfs; A Bruns; C Esche; P Lehmann; T Ruzicka; A Rütten; W Friedl; P Propping
Journal:  Hum Genet       Date:  1996-12       Impact factor: 4.132

9.  Constitutive deficiency in DNA mismatch repair: is it time for Lynch III?

Authors:  K E A Felton; D M Gilchrist; S E Andrew
Journal:  Clin Genet       Date:  2007-06       Impact factor: 4.438

10.  The molecular basis of Turcot's syndrome.

Authors:  S R Hamilton; B Liu; R E Parsons; N Papadopoulos; J Jen; S M Powell; A J Krush; T Berk; Z Cohen; B Tetu
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

  10 in total
  4 in total

1.  [Female patient with Muir-Torre syndrome].

Authors:  N Negraszus; K Jöhrens; E Bertelmann
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

2.  Glioblastoma multiforme in the Muir-Torre syndrome.

Authors:  Zev A Binder; Michael W Johnson; Avadhut Joshi; Christine L Hann; Constance A Griffin; Alessandro Olivi; Gregory J Riggins; Gary L Gallia
Journal:  Clin Neurol Neurosurg       Date:  2011-02-01       Impact factor: 1.876

Review 3.  How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies.

Authors:  Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

4.  Generational Expression of Muir-Torre Syndrome in a Canadian Family.

Authors:  Kaitlin Alexandra Vanderbeck; R Gary Sibbald; Nirosha Murugan
Journal:  Case Rep Dermatol Med       Date:  2016-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.